Neurocrine Biosciences
NBIX
#1407
Rank
A$22.11 B
Marketcap
A$219.98
Share price
-0.76%
Change (1 day)
15.63%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): A$1.19 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$3.10 Billion. In 2025 the company made an earning of A$0.89 Billion, an increase over its 2024 earnings that were of A$0.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.19 B33.87%
2025 A$0.89 B3.9%
2024 A$0.85 B96.41%
2023 A$0.43 B41.13%
2022 A$0.30 B73.74%
2021 A$0.17 B-8.82%
2020 A$0.19 B77.78%
2019 A$0.10 B49.83%
2018 A$73.28 M-142.57%
2017 -A$0.18 Billion-14.73%
2016 -A$0.21 Billion53.15%
2015 -A$0.14 Billion46.25%
2014 -A$90.14 Million29.66%
2013 -A$69.52 Million-3530.8%
2012 A$2.02 M-95.73%
2011 A$47.46 M
2009 -A$66.73 Million-45.38%
2008 -A$0.13 Billion-58.87%
2007 -A$0.3 Billion87.3%
2006 -A$0.16 Billion351.97%
2005 -A$35.09 Million-52.09%
2004 -A$73.24 Million-10.98%
2003 -A$82.27 Million
2001 -A$61.41 Million
1999 -A$27.7 Million108.32%
1998 -A$13.3 Million
1996 A$4.05 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$14.81 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$9.23 B 725.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$43.55 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.11 B-89.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$58.44 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$0.13 B-88.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$6.71 Million-100.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.37 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK